Scythian Biosciences completes sale of Go Green

1 minute read
30 November 2017
Client work

Team:

Peter Simeon

On Nov. 30, 2017, Scythian Biosciences Corp. (TSXV: SCYB) (Frankfurt: 9SB) (OTC Pink: SCCYF) announced that it had entered into a share purchase agreement to sell its wholly-owned subsidiary Go Green B.C. Medicinal Marijuana Ltd. to 1065703 B.C. Ltd.

Scythian is a research and development company committed to finding a solution for the prevention and treatment of concussions and traumatic brain injury with its proprietary Cannabinoid combination. Divesting of Go Green is not anticipated to have any material impact on Scythian’s operations.

Gowling WLG advised Scythian in this transaction with a team that included Peter Simeon and Susana Fonseca.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.
Related   Cannabis, Mergers & Acquisitions

Team

Related Insights & Resources

View all insights Related Insights & Resources
Client work
15 January 2024 Red White & Bloom Brands transitions to international cannabis company through closing of Aleafia transaction
Client work
17 November 2023 Khiron Life Sciences closes sale of its European business
Client work
04 January 2023 Atlas Global Brands Inc. completes RTO

Team

Download or print PDF